Wegovy once-daily oral weight-loss pill draws high interest, Novo Nordisk says

Novo Nordisk says its newly approved once-daily oral Wegovy pill launched in U.S. markets after FDA approval in December 2025 and is seeing strong interest; the company reported trial results similar to the injectable and wide pharmacy availability at about 70,000 locations.

Novo Nordisk has launched an oral, once-daily version of Wegovy after FDA approval in December 2025, and company executives say the pill began U.S. sales on Monday. The product is described as the first oral GLP-1 approved for weight loss. Novo Nordisk's U.S. operations executive Dave Moore told a business program that many patients who avoided injections had been waiting for a pill and that interest is high. Key facts: - The oral Wegovy pill was approved by the U.S. Food and Drug Administration in December 2025 and launched in U.S. markets on Monday. - Novo Nordisk says clinical trials show the oral pill delivers weight loss results similar to the injectable Wegovy, according to executive comments. - The company reported the pill will be available at about 70,000 pharmacies nationwide, including major retailers such as CVS and Costco and platforms like GoodRx. - Reported pricing cited insured eligible customers paying about $25 per month and uninsured customers paying about $149 per month for the semaglutide pill. - Novo Nordisk highlighted that both the injection and the pill carry a secondary indication to reduce cardiovascular disease risk and that the FDA classifies the drug as a preventative heart disease medication. - The company said research and development work is ongoing, and a rival maker is reported to be nearing approval for its own oral GLP-1 product. Summary: The launch expands availability of an oral GLP-1 option for weight loss and is described by company leaders as drawing strong patient interest, particularly from people who avoided injections. The pill's clinical trial results are reported as similar to the injectable form, and broad pharmacy distribution and stated pricing were highlighted. Regulatory and R&D developments, including a reported rival oral GLP-1 nearing approval, are noted as the next developments to watch.